NCT03291847View on ClinicalTrials.gov

Maternal Buprenorphine-naloxone Treatment and the Infant

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

December 27, 2022

Study Completion Date

December 15, 2023

Conditions
Maternal Opioid Use DisorderOpioid Exposed Infant
Interventions
DEVICE

fetal monitoring

Maternal fetal monitoring

DRUG

Buprenorphine Naloxone

Treatment for opioid use disorder

Trial Locations (1)

21224

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT03291847 - Maternal Buprenorphine-naloxone Treatment and the Infant | Biotech Hunter | Biotech Hunter